Charmaine Hebert, NP
Family · Lafayette, LANPI 1225341019
Payments from drug & device makers
Across 211 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$692
- Lilly USA, LLC$538
- AstraZeneca$359
- Novo Nordisk$320
- Boehringer Ingelheim$273
- Takeda Pharmaceuticals U.S.A., Inc.$185
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,540100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $692 |
| Lilly USA, LLC | 34 | $538 |
| AstraZeneca | 24 | $359 |
| Novo Nordisk | 19 | $320 |
| Boehringer Ingelheim | 15 | $273 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $185 |
| Exact Sciences | 7 | $116 |
| Noven Therapeutics, LLC | 6 | $112 |
| Amgen | 7 | $106 |
| Itamar Medical Inc | 1 | $91 |
| Astellas Pharma US Inc | 6 | $91 |
| Pfizer | 4 | $90 |
| Novartis | 5 | $89 |
| Abbott | 4 | $84 |
| Johnson & Johnson | 4 | $59 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Daiichi Sankyo Inc. | 2 | $36 |
| GSK | 2 | $34 |
| Eisai Inc. | 2 | $33 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 7 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Bausch Health US, LLC | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Silk Road Medical, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Merck | 1 | $14 |
How this compares
$3,540 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 72 | $84,366 |
| GlyxambiEmpagliflozin/Linagliptin | 66 | $52,968 |
| MounjaroTirzepatide | 46 | $50,708 |
| OzempicSemaglutide | 39 | $36,318 |
| FarxigaDapagliflozin Propanediol | 34 | $30,944 |
| TradjentaLinagliptin | 17 | $12,829 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $5,874 |
| Rosuvastatin Calcium | 391 | $5,563 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $4,605 |
| Pravastatin Sodium | 234 | $3,816 |
| Levothyroxine Sodium | 393 | $3,069 |
| Valsartan | 107 | $2,810 |
| Pantoprazole Sodium | 185 | $2,602 |
| Ezetimibe | 74 | $2,596 |
| Ibandronate Sodium | 53 | $2,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $273 | $150,162155 claims |
| Lilly USA, LLCMounjaro | $538 | $50,70846 claims |
| Novo NordiskOzempic | $320 | $36,31839 claims |
| AstraZenecaFarxiga | $359 | $30,94434 claims |
| AbbVieSynthroid | $692 | $99624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Lafayette
- Rebekah GarrardLafayette$105K
- Jorge MenaLafayette$27K
- Amanda KeysLafayette$27K
- Shanna JohnsonLafayette$22K
- Layne LemaireLafayette$13K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.